20n Bio Inc.

20n Bio Inc. is a biotech firm focused on discovering and developing cyclic peptides for therapeutic applications, utilizing innovative high-throughput screening technologies to address unmet medical needs in various therapeutic areas. Founded in 2021 in the US, 20n Bio Inc. specializes in the discovery and development of cyclic peptides.

Led by CEO Mingfu Zhu, the company raised USD 3. 3 mn in Seed funding on December 17, 2021, from BlueRun Ventures, which represents its first major investment round. The firm's operations are based in the United States, with a focus on markets in North America and Europe. 20n Bio specializes in the discovery and development of cyclic peptides for therapeutic use, leveraging a proprietary high-throughput screening platform that can evaluate trillions of peptides simultaneously.

This technology facilitates the identification of high-affinity peptides with optimal therapeutic properties, which can be utilized in various modalities such as oral peptides, radioligand therapy, and peptide-drug conjugates. The company aims to address significant unmet medical needs across multiple therapeutic areas, including metabolic disorders and complex cancers, by providing innovative peptide drugs that target diverse biological pathways. 20n Bio's clients include pharmaceutical and biotechnology companies with which they partner through licensing agreements for early-stage peptide candidates and customized solutions, thereby enhancing the drug development process. The firm primarily targets markets in North America and Europe, focusing on regions with a robust demand for advanced therapeutic solutions.

20n Bio generates revenue through strategic partnerships and licensing agreements with pharmaceutical and biotechnology firms, facilitating the development and commercialization of novel peptide therapeutics. Transactions typically occur through B2B agreements where clients license early peptide candidates that emerge from 20n Bio's high-throughput discovery platform. The company offers tailored solutions to assist partners in bringing these therapeutics to market efficiently, which can involve milestone payments and royalties based on the success of the developed products. Their revenue structure may include various collaboration frameworks, though specific pricing plans and financial terms related to individual services or products are not publicly disclosed.

The company’s flagship initiatives, encompassing the advanced peptide discovery platform, form the backbone of its revenue-generating activities. Following its Seed funding of USD 3. 3 mn in December 2021, 20n Bio plans to expand its scientific team and establish a robust discovery platform. The funding will support the initiation of multiple early studies in oncology and other genetic diseases, with a strategic focus on expanding into new markets, particularly in North America and Europe, by targeting pharmaceutical collaborations.

The company aims to enhance its product offerings and accelerate the development of its peptide therapeutics, thereby solidifying its position in the biotechnology sector.